Results 11 to 20 of about 119,061 (97)

Coded aperture and Compton imaging for the development of 225 Ac-based radiopharmaceuticals. [PDF]

Medical Physics (Lancaster), 2022
BACKGROUND Targeted alpha-particle therapy (TAT) has great promise as a cancer treatment. Arguably the most promising TAT radionuclide that has been proposed is 225 Ac.
E. Frame, K. Bobba, D. Gunter, L. Mihailescu, A. Bidkar, R. Flavell, K. Vetter   +6 more
semanticscholar   +1 more source

Efficacy and Safety of Actinium-225 Prostate-Specific Membrane Antigen Radioligand Therapy in Metastatic Prostate Cancer: A Systematic Review and Metanalysis

Medical Principles and Practice, 2023
Background: Actinium-225 (Ac-225) labelled PSMA RLT has been tested recently in metastatic castration-resistant prostate cancer (mCRPC), with encouraging results.
G. Parida, Raj Abhisek Panda, Komal Bishnoi, K. Agrawal   +3 more
semanticscholar   +1 more source

RYZ101 (Ac-225 DOTATATE) Opportunity Beyond Gastroenteropancreatic Neuroendocrine Tumors: Preclinical Efficacy in Small Cell Lung Cancer.

Molecular Cancer Therapeutics, 2023
Overexpression of somatostatin receptors (SSTRs), particularly SSTR2, is found in gastroenteropancreatic neuroendocrine tumors (GEP-NETs), and subsets of other solid tumors such as small cell lung cancer (SCLC). SCLC accounts for approximately 13%-15% of
Guangzhou Han, Eunmi Hwang, Fanching Lin, R. Clift, Daniel Kim, M. Guest, E. Bischoff, S. Moran, Gary Li   +8 more
semanticscholar   +1 more source

Actinium-225 production with an electron accelerator [PDF]

Journal of Applied Physics, 2021
There has been growing clinical evidence of the value of targeted alpha therapy for the treatment of several cancers. The work has been slowed by the lack of availability of the key alpha emitting isotopes, especially Ac-225.
W. Diamond, C. Ross
semanticscholar   +1 more source

Recent Innovations and Nano-Delivery of Actinium-225: A Narrative Review

Pharmaceutics, 2023
The actinium-225 (225Ac) radioisotope exhibits highly attractive nuclear properties for application in radionuclide therapy. However, the 225Ac radionuclide presents multiple daughter nuclides in its decay chain, which can escape the targeted site ...
Sipho Mdanda, Lindokuhle M Ngema, A. Mdlophane, M. Sathekge, J. Zeevaart   +4 more
semanticscholar   +1 more source

Treatment of Patients with Acute Myeloid Leukemia with the Targeted Alpha-Particle Nano-Generator Actinium-225-Lintuzumab.

Clinical Cancer Research, 2022
PURPOSE The anti-CD33 antibody lintuzumab has modest activity against acute myeloid leukemia (AML). To increase its potency, lintuzumab was conjugated to actinium-225 (225Ac), a radionuclide yielding 4 α-particles.
T. Rosenblat, M. McDevitt, J. Carrasquillo, N. Pandit-Taskar, M. Frattini, P. Maslak, Jae H. Park, D. Douer, D. Cicic, S. Larson, D. Scheinberg, J. Jurcic   +11 more
semanticscholar   +1 more source

In vitro dose effect relationships of actinium-225- and lutetium-177-labeled PSMA-I&T

European Journal of Nuclear Medicine and Molecular Imaging, 2022
Targeting the prostate-specific membrane antigen (PSMA) using lutetium-177-labeled PSMA-specific tracers has become a very promising novel therapy option for prostate cancer (PCa). The efficacy of this therapy might be further improved by replacing the β-
E. Ruigrok, G. Tamborino, E. de Blois, Stefan J. Roobol, N. Verkaik, M. De Saint-Hubert, M. Konijnenberg, W. V. van Weerden, M. de Jong, J. Nonnekens   +9 more
semanticscholar   +1 more source

Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists

Frontiers in Medicine, 2022
Peptide receptor radionuclide therapy (PRRT) has over the last two decades emerged as a very promising approach to treat neuroendocrine tumors (NETs) with rapidly expanding clinical applications. By chelating a radiometal to a somatostatin receptor (SSTR)
Mengqi Shi, Vivianne Jakobsson, Lukas Greifenstein, P. Khong, Xiaoyuan Chen, R. Baum, Jingjing Zhang   +6 more
semanticscholar   +1 more source

Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225

EJNMMI Research, 2022
Background PSMA-TO-1 (“Tumor-Optimized-1”) is a novel PSMA ligand with longer circulation time than PSMA-617. We compared the biodistribution in subcutaneous tumor-bearing mice of PSMA-TO-1, PSMA-617 and PSMA-11 when labeled with 68 Ga and 177 Lu, and ...
C. Meyer, V. Prasad, A. Stuparu, P. Kletting, G. Glatting, J. Miksch, C. Solbach, K. Lueckerath, L. Nyiranshuti, Shaojun Zhu, J. Czernin, A. Beer, R. Slavik, J. Calais, Magnus Dahlbom   +14 more
semanticscholar   +1 more source

Modulating the pharmacokinetic profile of Actinium-225-labeled macropa-derived radioconjugates by dual targeting of PSMA and albumin

Theranostics, 2022
Rationale: Small 225Ac-labeled prostate-specific membrane antigen (PSMA)-targeted radioconjugates have been described for targeted alpha therapy of metastatic castration-resistant prostate cancer.
F. Reissig, K. Zarschler, Z. Nový, M. Petřík, K. Bendová, D. Kurfurstová, J. Bouchal, Marie-Charlotte Ludik, Florian Brandt, K. Kopka, M. Khoylou, H. Pietzsch, M. Hajdůch, C. Mamat   +13 more
semanticscholar   +1 more source